Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Weill Medical College of Cornell University
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
University of Arizona
University of Chicago
Baylor College of Medicine
Northside Hospital, Inc.